Making a Difference in Cancer Prevention and Control
ECL Annual Meetings are open only to ECL member leagues and invited guests
These ECL meetings are kindly hosted by the Danish Cancer Society
Danish Cancer Society, Strandboulevarden 49, DK- 2100 Copenhagen Ø
For more information please write to
ECL Annual Meetings 2017
26 - 29 September 2017
Tuesday 26 September: 9:30 – 16:30 Patient Support Working Group (PSWG)
Tuesday 26 September: PSWG Dinner
Wednesday 27 September: 9:00 – 12:30 PSWG
Wednesday 27 September: 13:30 – 17:00 Access to Medicines Task Force
Wednesday 27 September: 9:00 – 18:00 European Code Against Cancer Workshop
Wednesday 27 September: 18:00 – 20.00 ECL Welcome Reception
Wednesday 27 September: 20:00 – 21.00 Board Meeting
Thursday 28 September: 10:00 – 17:00 Annual Conference
Thursday 28 September: 19:30 – 22:30 Official Dinner
Friday 29 September: 10:00 – 13:30 General Assembly
Friday 29 September: 13:30 – 15:00 Lunch / Board meeting
ECL Annual Conference
Is Cancer in Control?
Thursday 28 September 2017
10:00 to 17:00
10.00 - 10:25
Dorthe Crüger, Chairman, Danish Cancer Society
Sakari Karjalainen, President, Association of European Cancer Leagues
Christel Schaldemose, MEP TBC
10:25 – 12:30
TRANSFORMATION OF EUROPEAN CODE AGAINST CANCER
Chair: Hans Storm
Cancer prevention Europe – a new initiative in Prevention and communication
Speaker: Chris P. Wild, Director, International Agency for Research on Cancer (IARC)
Demographic changes and evolving patterns of risk factors will result in major increases in the cancer burden across Europe in the next two decades, while the costs of treatment spiral. This combination is a threat to sustainability of health care systems, indicating no country can treat its way out of the cancer problem. The only realistic approach is one that encompasses prevention, early detection and treatment. Cancer research provides the essential evidence-base for prevention, providing information on the burden, the causes and an evaluation of interventions and their implementation. Cancer prevention efforts in Europe would be strengthened by bringing together the diverse skills and partners needed under an integrated plan which avoids duplication and inefficiencies. In this context, a number of leading cancer research organizations have joined together to create a consortium, Cancer Prevention Europe (CPE) to complement the existing Cancer Core Europe consortium. This twin-track initiative (CPE and CCE) will build on the recognition that cancer biology is providing a “common soil” which can benefit both clinical and population approaches to cancer control. The objective of CPE is to reduce mortality and morbidity from cancer through primary prevention and earlier diagnosis at pre-malignant stages. This will be accomplished through research into the identification of novel targets for prevention, research into optimizing the implementation of known preventive strategies and dissemination of established best practices in prevention. The CPE partners wish to develop compatible infrastructures; common platforms for conducting prevention and implementation research; high standards of evidence review and dissemination practice. The first phase of CPE activities will be discussed during this presentation
(Presentation 30 mins – Q & A 15 mins)
From research hypothesis to public health changes – the whole grain story
Speaker: Anne Tjønneland, Head of Research, MD, PhD, DMSc, Danish Cancer Society
The presentation will give an overview, from the early observations on the association between dietary fiber and colorectal cancer, which was done by Burkitt in the late 1960’, until the knowledge we have today, based on intensive research on whole grain and health effects, based mainly on large population studies.
Some of the proposed mechanisms behind the effect of wholegrain on diseases, like colorectal cancer, type2diabetes and cardiovascular diseases will be described, and how this knowledge has been the basis for the international recommendations of whole grain intake from World Cancer Research Fund, and has also been the scientific evidence behind the Danish recommendations of 75 grams of whole grain intake per day and “The Danish Whole Grain Campaign”.
A campaign, which has managed to increase the availability of whole grain products in Denmark, and lifted the whole grain intake in Denmark substantially.
(Presentation 30 mins – Q & A 10 mins)
HPV- vaccines – results and challenges
Speaker: Mette Lolk Hanak, Head of Prevention, Danish Cancer Society
In 2009 HPV vaccination became part of the Danish Childhood Vaccination programme as an offer given to girls around the age of 12 years. Young women were also offered free vaccination during a period of two years. The programme was an immediate success and within a few years, the HPV vaccination coverage was up to 90 % for girls born 1998-2000. A few years ago reports about presumed serious side effects began to show. The reports about girls with unexplained symptoms gained massive attention from the press and on the social media. Soon the HPV vaccination coverage dropped dramatically and in 2016 the coverage was only 27 % for year group 2003. In spite of a renewed, positive safety assessment from the European Medicines Agency and strong recommendation of the HPV vaccination from authorities and doctors, the vaccination coverage is still very low. Apparently authorities have lost control of the situation - The challenge is how to communicate more effectively especially to the parents of young girls that HPV vaccination is safe and can save lives.
(Presentation 30 mins – Discussion and proposal for ECL statement on prevention 10 mins)
12:30 – 13:30
13.30 – 14.30
Chair: Jacqueline Godet, President, Professor, French Cancer League
Equal access to medicines & ECL Task Force
Speaker: MichelRudolphie, CEO, Dutch Cancer Society
Treatment - Equal access to medicines & ECL Task Force
Draft abstract drafted by ECL secretary
One of the core aspects of cancer control is access to effective medicines to treat and control the disease. In a time where cancer incidence has been rising in Europe, treatment has become crucial in controlling the burden of the disease at a national level. Scientific breakthroughs have occurred in the development of cancer medicines, offering new hope to patients where there may have been none before. However, these innovative medicines have in some cases come with a hefty price tag. Although the increase in innovative and promising treatments should be celebrated, patient access and availability should be central to the system. Some of the main contributing factors to this are inconsistent pricing policies that apply to the pharmaceutical industry, fragmented reimbursement decisions in national health bodies and a lack of transparency in the financial investment in research and development of new medicines.
In April 2016, the Dutch Cancer Society launched a coalition of ECL members on the topic of equal access to innovative cancer medicines. The newly formed ECL Task Force aims to facilitate an international network of ECL members to work together towards equal access to cancer medicines for all cancer patients. This presentation will focus on international aspects of access to cancer medicines, as well as the work done by the ECL task force.
(Presentation 20 mins)
Public Priority of Cancer Medicines in Denmark
Speaker: Dorthe Crüger, Chairman of the Danish Cancer Society, CEO Hospital Lillebælt, MD PhD.
Denmark has a long tradition of making rapid and systematic use of new cancer medicines. The last couple of years, new cancer medicines have been avoided as a standard treatment, as the expected effect was little and the side effects considerable.
From 2017, the new cancer medicine will also be assessed with a view to costs – so that expensive medicine with limited effect will not be used as a standard treatment.
The Danish Cancer Society works for personalised medicines, so the individual patient receives the right treatment – including being able to reject the treatment based on information regarding expected effects and side effects.
(Presentation 20 mins)
Discussion of presentations and related aspects (20 mins)
14.30 – 14.45
14.45 – 15.45
DIVESTING FROM TOBACCO INDUSTRY
Chair: Michael Henneberg Pedersen, Chief financial officer Danish Cancer Society
What could bring an oncologist to the table in the boardrooms of some of the world’s largest and most influential pension funds/finance companies?
Speaker: Bronwyn King, Founder and CEO, Tobacco Free Portfolios
Dr. Bronwyn King, an Australian oncologist and founder and CEO of Tobacco Free Portfolios will tell the story of how her earliest years in medicine, treating patients suffering from tobacco related disease, inspired to her to collaborate with and seek partners in the finance sector. Hear how this unique approach is driving change, with almost $5 billion dollars being redirected from investment in the tobacco industry. The finance sector has never before been an active part of the solution when it comes to addressing the global tobacco epidemic, but a new frontier has arrived with more and more finance leaders actively distancing themselves and their companies from the tobacco industry. And it’s only just beginning. Perhaps you might consider becoming a partner too?
(Presentation 40 mins – Discussion 20 mins)
15:45 – 16:45
Chair: Roisin Foster, Chief Executive, Cancer Focus Northern Ireland
Resilience and Cancer
Speaker: Peter Genter, Head of Cancer Counselling Centre, MS (psych)
Resilience refers to the processes that either promote well-being among cancer patients or protect them against the overwhelming influence of risk factors. There is an increasing research interest in promoting resilience among cancer patients and a Danish pilot study will be presented.
(Presentation 20 mins – Discussion 10 mins)
Collective Impact - a new approach to solve complex problems
Speaker: Elsebeth Kirk Muff, Ass. DirectorSocial Development Centre SUS
The collective impact approach is based on a committed effort from different organisations and sectors to solve a specific social problem. The Danish Cancer Society is involved in a collective impact project to improve health among socially disadvantaged young people in a Danish municipality.
(Presentation 20 mins – Discussion 10 mins)
16:45 – 17:00
CLOSING and practical information
Sakari Karjalainen, ECL President